Leading diagnostics companies, as well as academic institutions, have launched new solutions to refine patient stratification and personalize therapy, particularly in the context of PARP inhibitor (PARPi) treatment for ovarian and breast cancer. The gene discussed is PARP1; the disease is breast carcinoma.